Overall survival analysis
| Variable . | Class/cutoff . | n (%) . | Univariate analysis* . | Multivariate analysis† . | ||
|---|---|---|---|---|---|---|
| Hazard ratio of event risk . | P . | Hazard ratio of event risk . | P . | |||
| Bcl2‡ | IHC score > 0 | 53 (39.8) | 1.64 (0.843-3.188) | .15 | ||
| EBV‡ | IHC score > 0 | 29 (20.4) | 0.627 (0.243-1.618) | .33 | ||
| PD1 | IHC score > 1 | 8 (18.2) | 0.447 (0.055-3.625) | .45 | ||
| CD57 | IHC score > 1 | 42 (35.3) | 1.09 (0.497-2.373) | .84 | ||
| FOXP3 | IHC score > 1 | 97 (73.5) | 0.908 (0.415-1.987) | .81 | ||
| Tryptase | IHC score > 1 | 116 (83.5) | 1.86 (0.566-6.088) | .31 | ||
| TIA-1 | IHC score > 2 | 34 (24.5) | 2.4 (1.202-4.786) | .013 | 1.91 (0.841-4.331) | .12 |
| Granzyme B | IHC score > 1 | 40 (36.4) | 1.31 (0.618-2.779) | .48 | ||
| PS100 | IHC score > 1 | 77 (53.8) | 1.28 (0.651-2.522) | .47 | ||
| TopoIIa‡ | IHC score > 1 | 66 (49.3) | 2.85 (1.358-5.961) | .006 | 4.11 (1.663-10.136) | .002 |
| BFAR‡ | IHC score > 1 | 84 (70.6) | 0.798 (0.356-1.792) | .59 | ||
| Smad4 | IHC score > 0 | 20 (29.4) | 0.799 (0.287-2.224) | .67 | ||
| Bcl11A | IHC score > 1 | 68 (53.1) | 0.104 (0.04-0.268) | 2.90 × 10−6 | 0.103 (0.032-0.329) | .001 |
| CD20 | IHC score > 1 | 76 (53.9) | 0.322 (0.157-0.658) | .002 | 0.325 (0.135-0.781) | .012 |
| CD8 | IHC score > 1 | 54 (45.4) | 1.28 (0.601-2.728) | .52 | ||
| Stat1 | IHC score > 1 | 33 (42.9) | 1.13 (0.48-2.672) | .78 | ||
| BDCA2 | IHC score > 1 | 24 (35.3) | 1.28 (0.405-4.051) | .67 | ||
| Age | ≥ 45 y | 21 (14.9) | 2.56 (1.197-5.477) | .015 | 6.47 (2.321-18.019) | .001 |
| Sex | Female | 64 (44.8) | 0.44 (0.211-0.918) | .029 | 0.364 (0.147-0.904) | .03 |
| Ann Arbor | III-IV | 59 (41.3) | 1.39 (0.716-2.708) | .33 | ||
| B symptoms | Present | 47 (40.5) | 2.87 (1.301-6.331) | .009 | ||
| Bulky tumor | Present | 47 (40.5) | 5.25 (2.292-12.012) | 8.80 × 10−5 | ||
| Extranodal disease | Present | 19 (16.4) | 1.51 (0.569-4.014) | .41 | ||
| No. of nodal sites | ≥ 3 | 61 (48) | 1.11 (0.528-2.325) | .79 | ||
| Inguinal involvement | Present | 9 (9.4) | 2.74 (0.926-8.094) | .069 | ||
| ESR | ≥ 50 | 59 (48.4) | 1.2 (0.57-2.518) | .63 | ||
| Hemoglobin | ≥ 10.5 g/dL | 105 (78.4) | 0.795 (0.357-1.771) | .57 | ||
| White cell count | > 15 × 109/L | 27 (19.9) | 2.54 (1.222-5.269) | .013 | 2.79 (1.212-6.418) | .016 |
| Lymphocyte count | ≥ 0.6 × 109/L or ≥ 8% | 103 (82.4) | 0.533 (0.236-1.204) | .13 | ||
| Albumin level | ≥ 40 g/L | 47 (45.6) | 0.326 (0.131-0.812) | .016 | ||
| Variable . | Class/cutoff . | n (%) . | Univariate analysis* . | Multivariate analysis† . | ||
|---|---|---|---|---|---|---|
| Hazard ratio of event risk . | P . | Hazard ratio of event risk . | P . | |||
| Bcl2‡ | IHC score > 0 | 53 (39.8) | 1.64 (0.843-3.188) | .15 | ||
| EBV‡ | IHC score > 0 | 29 (20.4) | 0.627 (0.243-1.618) | .33 | ||
| PD1 | IHC score > 1 | 8 (18.2) | 0.447 (0.055-3.625) | .45 | ||
| CD57 | IHC score > 1 | 42 (35.3) | 1.09 (0.497-2.373) | .84 | ||
| FOXP3 | IHC score > 1 | 97 (73.5) | 0.908 (0.415-1.987) | .81 | ||
| Tryptase | IHC score > 1 | 116 (83.5) | 1.86 (0.566-6.088) | .31 | ||
| TIA-1 | IHC score > 2 | 34 (24.5) | 2.4 (1.202-4.786) | .013 | 1.91 (0.841-4.331) | .12 |
| Granzyme B | IHC score > 1 | 40 (36.4) | 1.31 (0.618-2.779) | .48 | ||
| PS100 | IHC score > 1 | 77 (53.8) | 1.28 (0.651-2.522) | .47 | ||
| TopoIIa‡ | IHC score > 1 | 66 (49.3) | 2.85 (1.358-5.961) | .006 | 4.11 (1.663-10.136) | .002 |
| BFAR‡ | IHC score > 1 | 84 (70.6) | 0.798 (0.356-1.792) | .59 | ||
| Smad4 | IHC score > 0 | 20 (29.4) | 0.799 (0.287-2.224) | .67 | ||
| Bcl11A | IHC score > 1 | 68 (53.1) | 0.104 (0.04-0.268) | 2.90 × 10−6 | 0.103 (0.032-0.329) | .001 |
| CD20 | IHC score > 1 | 76 (53.9) | 0.322 (0.157-0.658) | .002 | 0.325 (0.135-0.781) | .012 |
| CD8 | IHC score > 1 | 54 (45.4) | 1.28 (0.601-2.728) | .52 | ||
| Stat1 | IHC score > 1 | 33 (42.9) | 1.13 (0.48-2.672) | .78 | ||
| BDCA2 | IHC score > 1 | 24 (35.3) | 1.28 (0.405-4.051) | .67 | ||
| Age | ≥ 45 y | 21 (14.9) | 2.56 (1.197-5.477) | .015 | 6.47 (2.321-18.019) | .001 |
| Sex | Female | 64 (44.8) | 0.44 (0.211-0.918) | .029 | 0.364 (0.147-0.904) | .03 |
| Ann Arbor | III-IV | 59 (41.3) | 1.39 (0.716-2.708) | .33 | ||
| B symptoms | Present | 47 (40.5) | 2.87 (1.301-6.331) | .009 | ||
| Bulky tumor | Present | 47 (40.5) | 5.25 (2.292-12.012) | 8.80 × 10−5 | ||
| Extranodal disease | Present | 19 (16.4) | 1.51 (0.569-4.014) | .41 | ||
| No. of nodal sites | ≥ 3 | 61 (48) | 1.11 (0.528-2.325) | .79 | ||
| Inguinal involvement | Present | 9 (9.4) | 2.74 (0.926-8.094) | .069 | ||
| ESR | ≥ 50 | 59 (48.4) | 1.2 (0.57-2.518) | .63 | ||
| Hemoglobin | ≥ 10.5 g/dL | 105 (78.4) | 0.795 (0.357-1.771) | .57 | ||
| White cell count | > 15 × 109/L | 27 (19.9) | 2.54 (1.222-5.269) | .013 | 2.79 (1.212-6.418) | .016 |
| Lymphocyte count | ≥ 0.6 × 109/L or ≥ 8% | 103 (82.4) | 0.533 (0.236-1.204) | .13 | ||
| Albumin level | ≥ 40 g/L | 47 (45.6) | 0.326 (0.131-0.812) | .016 | ||
Univariate Cox proportional hazards regression model.
Cox proportional hazards regression model after backward stepwise variables selection procedure.
Bcl2, EBV, topoisomerase-2, and BFAR immunostainings were analyzed on Reed-Sternberg cells, whereas the results mentioned for all other antibodies were analyzed on reactive cells.